FDA grants priority review for Eagle's Ryanodex
This article was originally published in Scrip
Executive Summary
Shares of Eagle Pharmaceuticals climbed 6.9% on 20 March after the company revealed its new drug application (NDA) for Ryanodex (dantrolene) has been granted a priority review by the FDA, which set 22 July as the Prescription Drug User Fee Act action date.